|
Volumn 2, Issue 3, 2001, Pages 331-345
|
The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2 AMINO 5 PHOSPHONOVALERIC ACID;
CELL SURFACE RECEPTOR;
CYCLOSERINE;
DIZOCILPINE;
GLUTAMIC ACID;
ION CHANNEL;
MILACEMIDE;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY B6B21;
N METHYL DEXTRO ASPARTIC ACID;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT;
NEW DRUG;
NT 1;
NT 10;
NT 11;
NT 12;
NT 13;
NT 2;
NT 3;
NT 4;
NT 5;
NT 6;
NT 7;
NT 8;
NT 9;
PEPTIDE;
PHENCYCLIDINE;
UNCLASSIFIED DRUG;
ANIMAL CELL;
ANIMAL TISSUE;
ARTICLE;
BIOENGINEERING;
BRAIN HYPOXIA;
BRAIN ISCHEMIA;
COGNITION;
CONTROLLED STUDY;
DEATH;
DEPRESSION;
DISABILITY;
DRUG MECHANISM;
DRUG TARGETING;
EMBRYO;
HEALTH SURVEY;
MALE;
MENTAL DISEASE;
MODULATION;
NEUROLOGIC DISEASE;
NEUROPROTECTION;
NONHUMAN;
RABBIT;
RAT;
SCHIZOPHRENIA;
STROKE;
WORLD HEALTH ORGANIZATION;
AMINO ACID SEQUENCE;
ANIMALS;
ANTIBODIES;
ANTIBODIES, MONOCLONAL;
HUMANS;
LONG-TERM POTENTIATION;
MODELS, MOLECULAR;
MOLECULAR SEQUENCE DATA;
RABBITS;
RECEPTORS, N-METHYL-D-ASPARTATE;
|
EID: 0034851697
PISSN: 13894501
EISSN: None
Source Type: Journal
DOI: 10.2174/1389450013348399 Document Type: Article |
Times cited : (17)
|
References (87)
|